Nirali Shah

Hi, thank you for the opportunity. Firstly, congratulations on becoming the first company in India to receive the SEC recommendation. Just on that Cenobamate tablet, beyond the regulatory milestone, could you help us understand the commercial opportunity where we should focus primarily considering this opportunity?

Okay. And if you can quantify this opportunity?

In FY27?